Skip to main content
. Author manuscript; available in PMC: 2018 Apr 23.
Published in final edited form as: Oncogene. 2017 Oct 23;37(7):944–952. doi: 10.1038/onc.2017.400

Figure 3. Effects of targeted inhibitors on proliferation of BRAF, NRAS, and RAC1-mutant melanoma cell lines.

Figure 3

A) Western blots for activated PAK in the indicated cell lines. B) Cells were grown under standard conditions or treated with C) the MEK inhibitor PD325901 (100 nM), D) the PAK inhibitor Frax-1036 (100 nM), or E) the BRAF inhibitor vemurafenib (100 nM). Cell number was measured using an XCELLigence device.